Shattuck Labs plans phase 2 trial for SL-325 in hidradenitis suppurativa

Shattuck Labs (STTK) plans to start a Phase 2 trial in 2026 for SL-325 in hidradenitis suppurativa, with data expected in 2028. The company also appointed Shoba Ravichandran as Senior Vice President, Clinical Development. Cash runway is expected to last until 2029.

Strattec Security Corporation reported record annual revenue of $579.4 million for 2026, driven by pricing, cost actions, and operational improvements. The company reorganized its product portfolio and realized $6 million in restructuring savings, expanding gross margin to 16.5%. Strattec anticipates a challenging 2027 with a 2% decline in North American production and targets long-term gross margins of 18% to 20%. The company maintains a debt-free balance sheet with $108.2 million in cash and p

Shattuck Labs (STTK) rose 4.91% after two analysts initiated coverage with positive ratings. TD Cowen rated it buy, while Raymond James gave a strong buy and $18 price target. Both highlighted SL-325, a drug candidate for inflammatory bowel disease, citing its novel mechanism. The company reported $208.3M in cash and expects funding into 2029. Phase 2b trial for SL-325 is set to start in Q3.

H.C. Wainwright cut its price target for Shattuck Labs (NASDAQ:STTK) to $14 from $18 while keeping a Buy rating, after Shattuck reported Q2 2026 results on Aug. 11. Shattuck expanded its RECEPTIVE-CD1 Phase 2b trial to three doses and ~232 patients. The SL-325 Crohn’s trial remains on track for a Q3 2026 start. The article also notes a $75M public offering and warrant exercises.

Shattuck Labs, Inc. (STTK) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights – Phase 1 clinical trial results for SL-325 demonstrated a favorable safety profile, a potentially best-in-mechanism immunogenicity profile, and durable DR3 blockade of TL1A bi

Shattuck Labs (STTK) shares fell 1.8% pre-open after its Q2 2026 earnings. The company reported a net loss of $15.2 million versus $12.5 million a year earlier, and R&D rose 34% to $11.7 million. It cited favorable Phase 1 safety for SL-325 and said Phase 2b in Crohn’s is on track. Cash and investments were about $208.3 million.